Literature DB >> 19343042

Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population.

Hyo Seon Choi1, Youngin Lee, Kyong Hwa Park, Jae Sook Sung, Jong-Eun Lee, Eun-Soon Shin, Jeong-Seon Ryu, Yeul Hong Kim.   

Abstract

Cyclin-dependent kinase 5 (CDK5), a proline-directed serine/threonine kinase, which was originally known for its regulatory role in neuronal activities, has recently been suggested to play a role in extraneuronal activities. For example, a recent study detected overexpression of the CDK5 gene in non-small-cell lung cancer. Therefore, in order to explore the association of the CDK5 gene with lung cancer risk in a Korean population, the genotypes of the CDK5 promoter region were determined in 407 lung cancer patients and 402 normal participants. The result showed that the -904 G>A genotype affected susceptibility to lung cancer risk (odd ratios (OR)=1.53, 95% confidence interval (CI)=1.02-2.32). Furthermore, subsequent haplotype analysis of three single-nucleotide polymorphism (SNP) regions suggested that the A-G-C haplotype was associated with a higher overall risk of lung cancer (OR=1.59, 95% CI=1.16-2.18). These results suggest that CDK5 promoter polymorphisms contribute to the genetic susceptibility to lung cancer in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343042     DOI: 10.1038/jhg.2009.29

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  15 in total

1.  Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis.

Authors:  Jun-Li Liu; Xiao-Yan Wang; Bang-Xing Huang; Fang Zhu; Rui-Guang Zhang; Gang Wu
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

2.  Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.

Authors:  Zachary Levacque; Jesusa L Rosales; Ki-Young Lee
Journal:  Cell Cycle       Date:  2012-09-17       Impact factor: 4.534

3.  Phosphorylation of glutamyl-prolyl tRNA synthetase by cyclin-dependent kinase 5 dictates transcript-selective translational control.

Authors:  Abul Arif; Jie Jia; Robyn A Moodt; Paul E DiCorleto; Paul L Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

4.  Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.

Authors:  Fu-Ning Hsu; Mei-Chih Chen; Ming-Ching Chiang; Eugene Lin; Yueh-Tsung Lee; Pao-Hsuan Huang; Guan-Shun Lee; Ho Lin
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

Review 5.  The CDK inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas; Mindaugas Valius
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-30       Impact factor: 4.553

Review 6.  The Emerging Role of Cdk5 in Cancer.

Authors:  Karine Pozo; James A Bibb
Journal:  Trends Cancer       Date:  2016-10

Review 7.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

8.  Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration.

Authors:  Shuangbing Xu; Xu Li; Zihua Gong; Wenqi Wang; Yujing Li; Binoj Chandrasekharan Nair; Hailong Piao; Kunyu Yang; Gang Wu; Junjie Chen
Journal:  Mol Cell Proteomics       Date:  2014-08-05       Impact factor: 5.911

9.  Discovery and Evaluation of Polymorphisms in the AKT2 and AKT3 Promoter Regions for Risk of Korean Lung Cancer.

Authors:  Jae Sook Sung; Kyong Hwa Park; Seung Tae Kim; Yeul Hong Kim
Journal:  Genomics Inform       Date:  2012-09-28

10.  Retinoic Acid Induces Apoptosis of Prostate Cancer DU145 Cells through Cdk5 Overactivation.

Authors:  Mei-Chih Chen; Chih-Yang Huang; Shih-Lan Hsu; Eugene Lin; Chien-Te Ku; Ho Lin; Chuan-Mu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.